menu
    • menu
    [{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Curon Biopharmaceutical","amount2":1.3,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"14","companyTruncated":"Curon Biopharmaceutical \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Curon Biopharmaceutical

    Menu

    Curon Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curon Biopharmaceutical

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Curon Biopharmaceutical

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CN201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $1,300.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Acquires Investigational B-Cell Depletion Therapy, CN201, from Curon

                            Details : Under the terms of the agreement, Merck through a subsidiary acquired full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.

                            Brand Name : CN201

                            Molecule Type : Large molecule

                            Upfront Cash : $700.0 million

                            October 01, 2024

                            Lead Product(s) : CN201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $1,300.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curon Biopharmaceutical

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Curon Biopharmaceutical

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CN201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $1,300.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Puts Up Potential $1.3B to Acquire Curon’s B Cell Depletion Therapy

                            Details : Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN201, which is being evaluated in early-stage for treating acute lymphoblastic leukemia.

                            Brand Name : CN201

                            Molecule Type : Large molecule

                            Upfront Cash : $700.0 million

                            August 09, 2024

                            Lead Product(s) : CN201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : $1,300.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth